Former Executive of ScottCare, CardioNet and Lifewatch Corporation Set to Drive Sales of GEMS(TM) and Mobile Patient Monitoring Solutions into the U.S. Market
TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today announced that Mr. Daniel Pawlik has joined the organization as Vice President, Sales and Marketing for the United States effective January 6, 2014.
Mr. Pawlik has held senior executive positions within a number of large U.S.-based companies specializing in electrocardiogram (“ECG”) cardiac monitoring including Vice President of Sales, Marketing and Business Development U.S. Diagnostic Field Sales, Technologies and Contract Services for Ambucor Health Solutions, Inc., a subsidiary of ScottCare Corporation, and Vice President, Research Services and Technologies at LifeWatch Services Inc.
Pawlik was the Founder and CEO of Agility Centralized Research Services, Inc., a clinical research-based patient monitoring center providing telemedicine technology and operational outsourcing of patient monitoring for cardiac safety testing, contract project management, data collection and analysis to the pharmaceutical, medical device and academic research community. Agility Research was acquired initially by Biotel and is now a wholly owned subsidiary of Philadelphia based CardioNet, Inc. where Pawlik served as Vice President, Research Services Agility Centralized Research Services until recruited by ScottCare Corporation.
“Dan Pawlik is a welcome addition to the CardioComm Solutions team,” noted Simi Grosman, a member of the Company’s Board of Directors. “His knowledge of the cardiac monitoring landscape in the U.S. will allow us to accelerate our sales and development activities in 2014 and become a key player in this market. We will continue to build out the U.S. team under his leadership.”
CardioComm Solutions’ entry into the mobile cardiac telemetry (“MCT”) market was announced last year when it concluded a device integration and distribution deal with TZ Medical that brought the two companies into the MCT ECG and arrhythmia management market. Recently the Company announced completion of a custom MCT solution for Raytel Cardiac Monitoring, heralding the release of an off-the-shelf MCT software solution anticipated for early 2014.
In addition to adding bench strength to CardioComm Solutions’ management team, Daniel will be directly responsible for driving sales of GEMS(TM) and patient monitoring solutions in the U.S. The cardiac monitoring and cardiac rhythm management devices market is expected to grow to $23.3B over the next three years according to a report by MarketsandMarkets, a global market research and consulting company based in the U.S. Pawlik will also leverage his extensive network to identify HeartCheck(TM) PEN over-the-counter (OTC) sales and service opportunities in the U.S. market.
“I am very pleased and excited to be joining the CardioComm Solutions’ leadership team in their mission to build presence and grow market share within the U.S. health care market. CardioComm Solutions has developed an extremely innovative, flexible and effective patient monitoring and data management system in the GEMS(TM) software technology platform. The GEMS(TM) technology design and the capability of the Company’s development team will enable our introduction of a considerable number of innovative sales and service solutions that will help providers lower clinical costs, improve operational efficiencies and patient care while increasing service revenues,” said Daniel Pawlik. “I am confident CardioComm Solutions will be a welcomed technology partner to many health care organizations.”
“We are very pleased to welcome Dan to the CardioComm Solutions team,” said Etienne Grima, CardioComm Solutions’ CEO. “Dan has over 20 years of experience in the medical device and clinical research industry where he was responsible for the restructure of sales, marketing and business development operations, the integration of contract research services and development of large sales forces to support business expansion across the United States. Dan’s priorities will include driving the launch of our GEMS(TM) 4 product and MCT software as well as to assist in establishing new technology and service revenue streams from strategic partnerships with independent diagnostic testing facilities, health care providers and increasing HeartCheck(TM) related service revenues.”
About CardioComm Solutions
CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Canada, with offices in Victoria, B.C.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.